Epimedii Herba), was found to attenuate the progression of CKD and the loss of structural and functional integrity of kidney tissue, as evidenced by reduced serum levels of uric acid, creatinine, and blood urea nitrogen (Wang et al., 2020)
The result is a long-acting, injectable peptide broadly comparable in format to other GLP-1-based therapies such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), though retatrutide remains investigational and should not be considered equivalent to these licensed medicines
The CDC presented data on the investigations into vaccine-induced myocarditis deaths among people younger than 30 years old
While the results can be life-changing, it requires a commitment to a healthier lifestyle and regular check-ins with a medical professional
The information above outlines the similarities and differences between Ozempic and Victoza